“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Wednesday, August 27, 2025

Agenus


Agenus — A to Z Product Catalog

Marketed / Platform Assets

  • QS-21 Stimulon® (vaccine adjuvant)
    • Descriptor: Saponin-based vaccine adjuvant
    • Indications: Used to enhance immune response in vaccines (e.g. malaria, shingles, Alzheimer’s, NSCLC, melanoma)
    • Form: Used as component with partner vaccines

  • Prophage Series (Oncophage®, Prophage G-100/G-200, personalized cancer vaccines)
    • Descriptor: Heat shock protein-based personalized anti-cancer vaccines
    • Indications: Various cancers, including glioma and renal cell carcinoma
    • Form: Custom vaccine derived from patient's tumor

Investigational Pipeline — Checkpoint Modulators & Others (Fully owned)

  • Botensilimab (AGEN1181)
    • Descriptor: Fc-enhanced anti-CTLA-4 antibody
    • Indications: “Cold” and treatment-resistant cancers (e.g., MSS colorectal cancer, melanoma, pancreatic cancer)—often combined with Balstilimab
    • Form: Intravenous infusion; Phase 2 development

  • Balstilimab (AGEN2034)
    • Descriptor: Anti-PD-1 antibody
    • Indications: Backbone immunotherapy; used with Botensilimab in various cancers
    • Form: Intravenous infusion; Phase 2 development

  • Zalifrelimab
    • Descriptor: Anti-CTLA-4 antibody (selective)
    • Indications: Combined with other agents in trials including pancreatic cancer
    • Form: Investigational; clinical stage

Adoptive Cell and Adjuvant Platforms (via Subsidiaries)

  • MiNK Therapeutics (CAR-iNKT cell therapies)
    • Descriptor: Allogeneic invariant natural killer T cell-based immunotherapy
    • Indications: Advanced cellular immunotherapies for cancer
    • Form: Investigational; early-stage development


on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)